Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -16.67% 1.25 2,995,040 13:26:40
Bid Price Offer Price High Price Low Price Open Price
1.10 1.40 1.50 1.225 1.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.96 -1.34 -0.30 7
Last Trade Time Trade Type Trade Size Trade Price Currency
14:19:04 O 35,000 1.3844 GBX

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
28/3/202015:34Deltex Medical - a British success story!10,809
24/3/202013:06Deltex Medical - winner or doomed to fail? 277
19/6/201812:15Deltex Medical interview with new CEO1
06/6/201821:52Interview with Deltex Medical Group 1
14/7/201411:16Deltex Medical-Optimal Growth Stock10,005

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

Deltex Medical Daily Update: Deltex Medical Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 1.50p.
Deltex Medical Group Plc has a 4 week average price of 0.90p and a 12 week average price of 0.90p.
The 1 year high share price is 2.22p while the 1 year low share price is currently 0.90p.
There are currently 524,464,064 shares in issue and the average daily traded volume is 5,771,317 shares. The market capitalisation of Deltex Medical Group Plc is £6,555,800.80.
schloo: PS agree with Nobby that the results are a good opportunity to emphasise what Andy has achieved, in particular getting the business over the cash breakeven line and then to set out a clear way forward for growth. That would be a key step to driving a major correction in the share price
buywell3: Wonder if LID might offer 1 LID for 6 DEMG ? Would be generous with hindsight if the new NOMAD puts a decent note out that send LID back to 10p with a forward target of 20p plus ------------ RNS and a new LID NOMAD , N+1 Singer --------------- It is to be hoped that the new NOMAD , N+1 Singer will produce some decent new research notes to promote LiDCO and to show how their HUP initiatives are bearing fruit. A new forward looking LiDCO share price prediction will IMO follow to reflect recent acquisitions of smaller companies involved in the manufacture of Hemodynamic Monitors. Companies it should be noted that did not currently supply the NHS with 60% of its Hemodynamic Monitors as LiDCO does, plus recent increased HUP sales and sales into China. Companies that did not have a China based Hemodynamic Monitor manufacturing facility , as LiDCO has. htTps:// Covid -19 developments that buywell has eluded to in recent posts will one would think factor quite highly in such. ----------- The WHO has just declared Covid -19 a pandemic ----------- The new chancellor of the exchequer in the budget announcement, regarding the coming fight against Covid-19 has just announced : The NHS will get 1) Whatever it needs 2) Whatever it costs buywell recent posts has stated where this fight to save lives will take place , the battlefield will be in Hospital Intensive Care Units ( ICU's). This is where around 15% of patients that develop viral pneumonia , then circa 5% that develop septic shock and sepsis following on from viral pneumonia , will have to be treated. buywell believes the monies to buy Hmodynamic Monitoring equipment , which LiDCO has clinically showed to save lives in such circumstances , has been paid for by anaesthetists. Stats improvements in lives saved, reduction in length of stay (LOS) , and reduced complications stats , have to the best of my knowledge NOT been shown against the anaesthetists who bought and paid for the Hemodynamic Monitors but have shown improved stats for other parts of the Hospital. The NHS as we all know is now very stats driven In Italy ICU's are struggling to cope with the Covid-19 burden being placed upon them Germany has just announced it expects circa 60% of its population to acquire Covid-19 The junior minister for health Narine Dorries has just acquired it herself htTps:// buywell expects many other members of the government will also acquire it, some of the elder ones will get treated in ICU's. The time is therefore ripe for the NHS to purchase Hemodynamic Monitoring equipment in those Hospitals and Trusts where monies have been too tight to allow its purchase, the chancellor has just stated '' whatever the cost '' LiDCO buywell thinks , will be revisiting ALL Hospitals and Trusts to explain once more the merits of using their equipment via their HUP deal ( costs spread over 3 to 5 years) , with a list showing all those 25% of NHS Hospitals that have to date now switched to such a deal (HUP) with an NHS contact name , so that they can be referenced to gain relevant data regarding the NHS benefits to patients from the NHS horses mouth. Important: The use of Hemodynamic Monitoring in sepsis and septic shock has very clearly been clinically demonstrated hTtp:// hTtp:// Covid-19 will at some point have a vaccine made to fight against it, maybe 12 to 18 months away. Other Coronaviruses are on the way however which will have similar symptoms , viral pneumonia , septic shock and sepsis. buywell's point being : The purchase of Hemodynamic Monitoring units now to fight Covid-19 will NOT be wasted once it goes away. IMO LiDCO could receive many orders from around the world as death rates look set to rise due to a lack of ICU hospital beds and a lack of Hemodynamic Monitors. dyor
mrc2u: Don't know, but hopefully a couple of months earlier than last couple of yearsThe story is pretty simple: cash generating, profitable on a meaningful measure, growth set to come from X, Y, Z which ought to include new products, new business models, USAWould also be good to see some freshening up of the Board and advisers both to drive growth and an exit. Share price should have a good run even without this, but with it could have a great run MrC
schloo: More from twitter Hospital acquired AKI ought to be a major patient safety scandal. About one in twelve patients having a big operation go into hospital with healthy kidneys only to have them damaged, sometimes irreparably, by poor fluid management. This knocks years off their lives even for the lucky ones who don't end up on dialysis Quick worked example. 8 years since NICE recommended ODM be used on around 1,000,000 patients a year. Take up rounds to zero, so 8,000,000 patients of whom around 670,000 will have suffered AKI. 90% of those should have been avoided if they had followed the NICE guidance and used ODM to optimise circulation, so that is 600,000 patients who suffered avoidable harm. Cost at least £8,000 each so £4.8bn wasted. Say average survival reduction of 10 years meaning 6m life years also tossed casually away All that and the share price hammered too...
mrc2u: Doesn't sound right to me and suspect even more that this is not being announced to protect directors who filled their boots. The test here is about whether the news will move the share price and it did, so it should have been announced. The compromise is to announce on REACHThe 18-24 months comment is facile. Imagine if they announced a deal with a major corporate or hospital chain to start in 18-24 months which would treble sales. Of course that would have to be announced. Furthermore, 18-24 months falls within the period normally covered by market expectationsAnyway, a decent 400,000 buy has just gone through so onwards & upwards
gnnmartin: Good news indeed, thanks zho for posting. There is no up front cash or commitment to purchase (as far as we know), so I expect that was the reason why there was no RNS. I expect DEMG are rightly cautious about putting out RNS that might be dismissed by some as pumping. When the share price has been hammered shareholders understandably want good news broadcast, but equally understandably news may be viewed cynically
arf dysg: It's not a share, it's a company. Alternatively, if you're asking "how is the share price doing?" then the answer is blindingly obvious. If you can't see the share-price chart, then how will you see these answers, which tell you to look at the share price chart?
gbenson1: The share price action in DEMG never fails to amaze me, only the other day somebody bought 1 million+ shares and the price never budged, today there are in the region of 900k of sales and the Sp drops 16%, something is a foot, hopefully all will be revealed in the following days!!
schloo: Agreed although I don't think acquirers will be that bothered by the balance sheet. Cheetah never generated any cash and Baxter still paid a very high price Cheetah raised $12m of equity in 2017 and $7m more in 2018, none of it from new investors, suggesting it was a struggle. They then raised another $20m in venture debt earlier this year so balance sheet can not be pretty For DEMG, as a listed company whereas Cheetah was private, the key point about being cash flow positive is that there is no longer any incentive for the market to massively undervalue the company in anticipation of buying new shares super cheap in a placing The Cheetah deal shows that someone might well be willing to pay big money for DEMG right now, but it simply won't happen until the share price gets to a half sensible place. No reason, now its cash positive, why that should not happen now either
buywell3: A subscription raising £1.125 million by way of new convertible loan notes due 2019 ("Loan Notes") with an interest rate of 8% and a conversion price of 6 pence. The Loan Notes are repayable in full on the third anniversary of their date of issue although they may be prepaid in whole or in part at the Company's discretion at any time. Loan Notes The Company intends to raise £1.125 million by the issue of the Loan Notes. Of these, Imperialise Limited (a company associated with Nigel Keen, non-executive Chairman of the Company), has agreed to subscribe for £500,000 nominal amount of the Loan Notes. The Loan Notes are unsecured and interest is payable at 8% per annum. The Loan Notes are repayable in full on the third anniversary of their date of issue although they may be prepaid in whole or in part at the Company's discretion at any time. The Loan Notes are convertible at any time up until repayment into 18,750,000 ordinary shares at the effective price of 6p, being a premium of 30 per cent. over the share price at close of business on 2 February 2016 and a premium of 50 per cent. over the Issue Price. The Company can also enforce conversion if the ordinary share price is equal to or exceeds 18p for any period of 30 consecutive days. If the Company elects to prepay all or any of the Loan Notes, it will issue to the note holders warrants to subscribe for ordinary shares at 6 pence per share (at the rate of 5,000 warrants for every £300 nominal of Loan Notes repaid (and pro rata for any greater or lesser amount repaid)). Such warrants will be exercisable within the same period as corresponds to the conversion rights previously attaching to the Loan Notes prepaid.
Deltex Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Deltex Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200329 06:05:20